

Forxiga trial shows clinically meaningful improvements in glycemic control among patients aged 10–17 years

October 11 2023



Credit: CC0 Public Domain

Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for

patients treated with Forxiga (dapagliflozin) compared with patients receiving placebo. Adjusted mean change in A1C was -0.62% for Forxiga versus $+0.41\%$ for placebo, a difference of -1.03% (95% CI: $-1.57-0.49$; p

Citation: Forxiga trial shows clinically meaningful improvements in glycemic control among patients aged 10–17 years (2023, October 11) retrieved 3 May 2024 from <https://medicalxpress.com/news/2023-10-forxiga-trial-clinically-meaningful-glycemic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.